High-dose melphalan at 200 mg/m 2 can be administered in 1 day or over 2 consecutive days before autologous hematopoietic cell transplantation (HCT) for multiple myeloma (MM). Limited data exist on the comparison of the two dosing schedules. A retrospective study of 278 consecutive MM patients receiving high-dose melphalan from January 2010 to December 2012 was conducted. Objectives were to compare the length of hospitalization, toxicity profile, response rates, PFS and OS. One hundred and eighty five patients received 2-day dosing and 93 received 1-day dosing. The two end points of the 95% confidence interval (CI) for the difference did not exceed the preselected margin, therefore the length of hospitalization was considered equivalent. No significant differences were found for response rates, PFS and OS. The toxicity profile was similar with the exception of more frequent ⩾ grade 3 oral mucositis in the 2-day group (13.5% vs 5.4%; odds ratio 3.07 (95% CI:1.11-8.48); P = 0.03). High-dose melphalan, given either in 1 day or over 2 days, produced comparable treatment outcomes except for increased grade 3/4 mucositis in the 2-day regimen. One-day dosing could shorten the hospital stay by 1 day and may allow better resource utilization.
INTRODUCTION
Multiple myeloma (MM) is an incurable clonal B-cell neoplasm characterized by proliferation of malignant plasma cells in the BM, presence of monoclonal protein in the blood and/or urine and associated organ dysfunction.
1,2 MM comprises of~10% of all hematologic malignancies. OS of MM patients have steadily increased over the past few decades in part owing to the implementation of high-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT), availability of novel agents and improved supportive care. 3, 4 Recent incorporation of lenalidomide to post-transplant maintenance therapy improved PFS, setting the stage for further incremental survival improvement. 5, 6 Although high-dose melphalan 200 mg/m 2 is established as the standard conditioning regimen for autologous HCT, the practice variations exist on the dosing schedule. [7] [8] [9] High-dose melphalan can be administered over 1 day or given over 2 consecutive days (100 mg/m 2 /day). Adverse events deriving from high-dose melphalan occur in a dose-dependent fashion. Grazziutti et al. 10 found higher milligram per kilogram melphalan doses and renal dysfunction (both reflecting increased melphalan exposure) being the key pre-transplant factors for severe oral mucositis following autologous HCT in myeloma patients. Palumbo et al. 11 demonstrated a greater incidence of gastrointestinal side effects in patients with MM who received high-dose melphalan at 200 mg/m 2 vs patients who received melphalan 100 mg/m 2 as conditioning for tandem autologous HCT, where all doses of melphalan were given over 1 day. However, neither of the aforementioned studies compared toxicity profiles between administering the same total dose of melphalan over 1 day vs 2 days and direct comparative analyses have not been conducted between 1-day and 2-day high-dose melphalan for autologous HCT evaluating toxicity, length of hospitalization, response and survivals. Therefore, we conducted a single-center retrospective comparison between MM patients who received 1-day vs 2-day high-dose melphalan and underwent autologous HCT to evaluate post-transplant outcomes.
PATIENTS AND METHODS
The study was reviewed and approved by the University of South Florida Institutional Review Board with a waiver of informed consent. In March 2012, the Department of Blood and Marrow Transplantation at the Moffitt Cancer Center changed the high-dose melphalan conditioning regimen from 2-day dosing (100 mg/m 2 /day for 2 days) to 1-day dosing (200 mg/m 2 /day). A comprehensive list of consecutive MM patients who underwent autologous HCT from January 2010 to December 2012 was generated from our database, BRAIN (Blood and Marrow Transplant Research Analysis and Information Network). Electronic medical records were reviewed. Majority of transplant recipients underwent autologous HCT as inpatient.
Eligible patients were at least 18 years of age, had a primary diagnosis of MM and underwent high-dose melphalan at 200 mg/m 2 followed by autologous HCT. Patients who received 2-day dosing of melphalan consisted of those transplanted before March 2012; those in the 1-day group underwent HCT after that time period. Patients who received reduced dose melphalan (140 mg/m 2 ) were excluded. For recipients of tandem autologous HCT, only the first HCT was evaluated for primary and secondary end points.
Patients were risk stratified based on cytogenetics and/or FISH findings at diagnosis. The high-risk group was defined as the presence of at least one of the following: deletion of chromosome 13 by cytogenetics, hypodiploidy, t(4;14), t(14;16) or deletion 17p by FISH. 12 Other patients were classified as standard risk. Disease response (at the time of transplant and at day +90) was determined based on the International Myeloma Working Group Uniform Response Criteria. 13 Readmissions, if applicable, up to 30 days post initial discharge were also accounted for in the length of hospitalization. Toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) by the treating clinician from the initiation of conditioning therapy to day +30. Platelet engraftment was defined as the first day the platelet count ⩾ 20 000/μL for 7 consecutive days, independent of platelet transfusions, and neutrophil engraftment was defined as the first day the absolute neutrophil count ⩾ 500 cells/μL for 3 consecutive days.
Administration of high-dose melphalan and supportive care
All patients received high-dose melphalan at 200 mg/m 2 . Patients in the 2-day dosing regimen received the total dose over 2 days (days − 3 and − 2, each infused over 45 min), whereas patients in the 1-day dosing regimen received the total dose in 1 day (day -2, infused over 45 min). Antibacterial, antiviral and antifungal prophylaxes were provided based on institutional standards. Antiemetic prophylaxis according to institutional guidelines was administered to all patients: ondansetron 24 mg p.o. and dexamethasone 18 mg p.o. were given 60 min before melphalan on days − 3, − 2 and − 1 for patients in the 2-day group and on days − 2 and − 1 for patients in the 1-day group. Lorazepam 1 mg either p.o. or i.v. every 6 h was given for nausea and/or vomiting as needed. All patients were provided with ice chips 5 min before the start of the melphalan infusion, during the infusion and for 15 min after the end of the infusion.
14 Growth factor support with filgrastim was initiated on day +7 until ANC ⩾ 1500 cells/μl. Supportive care and other institutional standards did not change over the reporting period.
Statistical analyses
For the primary end point of length of hospitalization, Schuirmann's two one-sided tests approach was utilized to assess equivalence between the two treatment groups. 15 The 2-day dosing group was considered the control group. It was assumed that the length of hospitalization of the 1-day group is equivalent to that of the 2-day group if the absolute value of the difference between the two groups does not exceed an equivalence margin of 2.5 days (15% of the mean length of hospitalization of the 2-day group). A sample size of 278 patients (185 subjects for the 2-day group and 93 subjects for the 1-day group) achieves 98% power at a 5% significance level when the true difference between the means is 0 with the s.d. of 4.67 and the equivalence limits being − 2.5 and 2.5 days. To reduce any biases owing to confounding variables, the subjects were stratified into four subgroups based on the propensity score, which served as a stratification variable. Propensity score was defined as the probability of receiving 1-day melphalan for a patient with specific prognostic factors that included age, Karnofsky performance status at the time of transplant, disease status and cytogenetics/FISH at the time of diagnosis, prior number of therapies and infused CD34
+ stem cell dose. The confidence interval (CI) for the difference in the length of hospitalization between the two groups was computed and adjusted for the stratification variable. If the CI is completely contained within the margin of − 2.5 and 2.5 days, then the 1-day group is equivalent to the 2-day group.
For the secondary end points, differences in toxicity profile and response rates between the two groups were evaluated at a two-sided 5% level using a stratified logistic regression model or the Cochran-MantelHaenszel test as appropriate. The Kaplan-Meier curves were formulated to represent PFS and OS between both treatment groups and the difference between the two groups in PFS and OS was evaluated by a stratified logrank test in order to account for the effect of the stratification variable. As an exploratory analysis, the relative reduction of either monoclonal spikes or representative serum-free light chain values before and after autologous HCT at day +90 were compared between the two groups using the Wilcoxon rank sum test. Patient characteristics were summarized using descriptive statistics including mean, median, s.d. and range for continuous measures, and proportions and frequencies for categorical measures. Analysis was performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Among the 278 MM patients who received high-dose melphalan followed by autologous HCT over the 3-year study period, 185 patients received 2-day dosing (100 mg/m 2 /day × 2 days) and 93 patients received 1-day dosing (200 mg/m 2 in 1 day). Patient demographics were stratified based on treatment regimens, 1-day vs 2-day melphalan, and grouped as disease-related and transplant-related characteristics (Table 1) . Treatment groups were Abbreviations: CyBorD = CY, bortezomib, dexamethasone; HCT = hematopoietic cell transplantation; PD = partial disease; RD = lenalidomide, dexamethasone; RVD = lenalidomide, bortezomib, dexamethasone; sCR = stringent CR; SD = stable disease; VD = bortezomib, dexamethasone; VGPR = very good PR.
balanced with respect to sex, age at transplant, cytogenetics/FISH at diagnosis and prior number of therapies. Disease status at the time of transplant was different between both groups, with more patients achieving a PR/very good PR: 83% vs 76%, and CR/ stringent CR: 16% vs 14%, in the 1-day vs 2-day dosing group, respectively (P = 0.03). Transplant-related variables (Karnofsky performance status at the time of transplant, time from diagnosis to transplant and infused CD34 + cell dose) were similar between the treatment groups.
Outcomes Length of hospitalization. The median length of hospitalization, from date of admission to hospital discharge, was 17 (range, 4-36) days vs 16 (range, 4-27) days for the 2-day dosing group and the 1-day dosing group, respectively. The two end points (−0.01 and 2.42 days) of the 95% CI for the difference did not exceed the preselected margin, therefore the length of hospitalization of the 1-day group is considered equivalent to the 2-day group. The CI for the difference between the two groups was adjusted for the stratification variable, which was defined using the propensity score.
Toxicity profile. Grade 3/4 oral mucositis occurred more frequently in those patients who received 2-day dosing of melphalan (14% vs 5%; odds ratio 3.07; 95% CI: 1.11-8.48; P = 0.03). The incidence of febrile neutropenia was similar between the treatment groups (64% vs 60% for the 2-day and 1-day dosing groups, respectively; P = 0.7) ( Table 2) . No other significant differences in the toxicity profile were found with regard to any grade of diarrhea, renal dysfunction or hepatic dysfunction.
No differences in supportive care during hospitalization between treatment groups was found with respect to use of opioid medications (both oral and/or i.v.), patient-controlled analgesia, total parenteral nutrition or antiemetic medications (refers to use of antiemetic medications other than the standard prophylaxis, such as prochlorperazine, promethazine, metoclopramide or scopolamine). The median time to platelet and neutrophil engraftment was 13 days and 12 days, respectively, for both treatment groups.
Response rates at day +90 post transplant. Disease response at day +90 between the treatment groups is shown in Table 3 . No significant differences were found between the two groups (P = 0.3). No differences were found between the treatment groups when these disease response categories (stringent CR +CR) were grouped together (42% vs 31% for the 2-day and 1-day groups, respectively; P = 0.09). Patients in the 1-day dosing group had an overall response rate of 91% vs 88% for the 2-day group (P = 0.5). As an exploratory end point, the relative reduction of monoclonal protein or serum-free light chains were compared between the two groups in available patients (n = 180 for 2-day dosing group and n = 91 for 1-day dosing group). The median Abbreviations: CI = confidence interval; OR = odds ratio; PCA = patient-controlled analgesia; TPN = total parenteral nutrition.
a Indicates antiemetic medication use beyond standard prophylaxis (ondansetron, dexamethasone and lorazepam) utilized, such as prochlorperazine, promethazine, metoclopramide or scopolamine. Abbreviations: ORR = overall response rate; PD = progressive disease; sCR = stringent CR; SD = stable disease; VGPR = very good PR.
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relative reduction of representative monoclonal spike or serumfree light chain values pre-and post HCT at day +90 were 55.5% in 2-day dosing group and 53% in 1-day dosing group (P = 0.7).
PFS and OS at day +180 post transplant. PFS at day +180 post transplant is shown in Figure 1 . No differences existed between the treatment groups with 86% of patients in the 2-day group and 85% in the 1-day group being free of progressive disease at 6 months post transplant (P = 0.3). OS at +180 days was 99% in the 1-day group vs 96% in the 2-day group (P = 0.1) (Figure 2) .
DISCUSSION
We performed a single-center retrospective analysis comparing the outcomes of the 2-day (n = 185) vs 1-day (n = 93) regimen of high-dose melphalan followed by autologous HCT in 278 myeloma patients over the 3-year period. The median length of hospitalization for both treatment groups was equivalent: 17 days vs 16 days for the 2-day and the 1-day dosing groups, respectively. The finding with regard to length of hospitalization is comparable to other studies for this patient population. Jagannath et al. OS. OS curves using the Kaplan-Meier method comparing 2-day dosing (solid line, n = 185) and 1-day dosing (dashed line, n = 93) after high-dose melphalan followed by autologous hematopoietic cell transplantation.
19 days in 75 myeloma patients who underwent autologous HCT; 60 of whom received high-dose melphalan 200 mg/m 2 over 2 days. In another study, Badros et al. 17 reported a median length of hospitalization of 16 days in 70 myeloma patients (who were 70 years of age and older) who received either high-dose melphalan at 200 mg/m 2 or 140 mg/m 2 (given over one day) before autologous HCT, suggesting the overall equivalency for 2-day vs 1-day high-dose melphalan administration.
In our study, the baseline patient characteristics were balanced including the age and risk stratification with the exception of disease status at the time of autologous HCT, with a slightly higher proportion of responsive patients in the 1-day group, which might reflect recent improvement in induction therapy efficacy. There was a higher stringent CR/CR rate noted in the 2-day dosing group (42% vs 31%), however, no significant association was found (P = 0.09). Owing to the limited follow-up time, we also evaluated the relative reduction in either monoclonal spikes or serum-free light chain levels before and after the transplant at day +90 as an exploratory analysis. The two groups did not differ in regard to the relative reductions in these values. There were no significant differences in the toxicity profile between the groups except for mucositis: patients in the 2-day group experienced significantly more ⩾ grade 3 oral mucositis compared with those in the 1-day group (14% vs 5%). Lilleby et al.
14 conducted a prospective, randomized study of cryotherapy (that is, ice chips) vs room temperature normal saline rinse during administration of high-dose melphalan and demonstrated significantly less grades 3-4 mucositis in cryotherapy compared with room temperature normal saline (14% vs 74%, P = 0.0005). Our center adopted cryotherapy as our institutional practice and the supportive care standards was consistent over the study period.
Several factors could influence the occurrence of mucositis following high-dose melphalan. Melphalan toxicity may correlate with its pharmacokinetic (PK)/pharmacodynamic profile. Vassal et al. 18 evaluated the PK/pharmacodynamic of high-dose melphalan administered over two consecutive courses (100 mg/m 2 every 21 days) before tandem autologous HCT in children with neuroblastoma and medulloblastoma. Prolonged platelet recovery and more gastrointestinal toxicity (specifically diarrhea and oral mucositis) were associated with a high area under the curve (AUC) of melphalan. Nath et al. 19 performed a population PK modeling in myeloma patients who received a median melphalan dose of 192 (range, 115-216) mg/m 2 before autologous HCT. Total melphalan AUC was significantly higher in patients who had ⩾ grade 3 oral mucositis. These findings support the notion that melphalan toxicity is associated with the level of systemic exposure or AUC, rather than a peak effect. Although melphalan PK was not performed in our study, it is possible that the 2-day regimen may have produced a prolonged level of systemic melphalan exposure compared with the 1-day dosing, which may explain the higher incidence of ⩾ grade 3 oral mucositis. Alternatively, other medications concomitantly used during the transplant may have altered the melphalan PK in one group more than the other.
The median times to platelet and neutrophil engraftment were equivalent in both groups in our study as corroborated by many other studies. [7] [8] [9] Similarly, the responses post transplant were equivalent in both treatment groups. Although the current study was not powered to detect the differences in survival, there were no differences in PFS or OS at day +180 post transplant between the two treatment groups. It is conceivable that the PFS and OS may differ over time as the 1-day group is likely receiving more maintenance therapy (data not shown) based on recent practice change. We acknowledge the following potential limitations of our analysis: first is the retrospective nature of this study and the constraints implicated with it. Second, although the sample size is relatively large, this is a single-center experience and the two groups were not treated simultaneously, and lastly the follow-up period is rather short (over 3 years) and the study is not suited for long-term outcomes for OS and PFS. In addition, the medical providers were not blinded to the treatment regimen, hence it might have affected the toxicity assessment and the toxicity was not evaluated prospectively.
In summary, this study albeit retrospective represents the first direct comparative analysis of 1-day vs 2-day high-dose melphalan administration for autologous HCT in MM patients. No significant differences in length of hospitalization, responses and survivals were found between the two groups except for a higher incidence of grade ⩾ 3 oral mucositis in the 2-day dosing group. Administering high-dose melphalan 200 mg/m 2 over 1 day before autologous HCT for patients with MM appears to be equivalent compared with the 2-day regimen. Transplant centers utilizing 2-day dosing could consider transitioning to 1-day dosing of highdose melphalan. One-day regimen would potentially help to reduce length of hospital stay by one day compared with 2-day dosing and may improve resource utilization without jeopardizing patient safety and treatment outcomes. Future studies on melphalan dosing for high-dose chemotherapy are neeeded to address the efficacy in high-risk MM patients and the tolerability in more frail patients.
